Leadingpharm Medical Technology
Revolutionizing the Global Drug Development Space

hina has always been a technological hotbed for innovation. Over the years, many companies have emerged in the Chinese healthcare ecosystem and went on to take up a global leadership role. And today, Leadingpharm Medical Technology—one of the technical pioneers of fine chemical and bulk drug intermediates—is on the same trajectory of bringing innovation to the Chinese healthcare landscape.

Headquartered in Zhongguancun High-tech Park of Beijing, China, Leadingpharm is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO, and CDMO services worldwide. Under the able leadership of Tao Xinhua, the chairperson at Leadingpharm, the company has been rated as “China’s Top 10 Pharmaceutical R&D Enterprises” for many years. Notably, most of Leadingpharm’s management team members have many years of working experience in domestic and foreign research institutions and pharmaceutical companies. In addition, their research experience includes professional fields such as new drug research and development, industrial transformation, pharmaceutical regulations, and capital operation. Thus far, Leadingpharm has developed more than ten different drug development processes at the lowest price brackets.

Leadingpharm has recently established six new platforms for both large and small molecule drug testing and screening, evaluation, and production. These six platforms comply with international standards (FDA, EMA, and NMPAGMP) while being certified by governing bodies like the Association for Assessment and Accreditation of Laboratory Animal Care International or AAALAC, China National Accreditation Service or CNAS, and Good Laboratory Practices (GLP). With the addition of these new platforms, Leadingpharm now possesses complete manufacturing facilities for pilot and scale-up experiments, along with two industrialized scale-up manufacturing bases.

Leadingpharm has recently established six new platforms for both large and small molecule drug testing and screening, evaluation, and production

Leadingpharm’s manufacturing base has production workshops and a quality inspection center, containing critical equipment for deep freezing, high-pressure hydrogenation, etc. Such innovative capabilities, driven by dual engines, can provide Leadingpharm’s clients with diversified services throughout pharmaceutical research and development. To this end, Leadingpharm has established a wide range of cooperative relations with twenty companies at home and abroad.

At this juncture, it is also important to note that Leadingpharm pays much attention to the stability of experiments, verification of analysis method, and the investigation of ‘out-of-specification’ or OOS results to ensure the accuracy and relevance of analytical data and provide the best service to its clients. Thus, Leadingpharm’s cooperative partners can obtain bulk drugs and intermediates with advanced technology at the lowest price. Going the extra step, Leadingpharm also sets up a strict management system and complete quality assurance systems for its clients. Leadingpharm maintains its quality assurance system on par with the pharmacopeia of European and American countries. Because of this, Leadingpharm has been able to help its cooperative partners for FDA drug master files (DMF) registration for many products in the U.S., along with other regulatory compliance needs of the EU, Australia, and Canada.

Supported by such robust technological advantage, rich experience, and powerful abilities in the field of medical research and development, Leadingpharm is now rapidly enhancing its capabilities in bulk drugs and intermediates, and establishing a stronger trademark in this field. It currently has the ability to develop clients’ products in quantities very small, like few grams to very large amounts weighing a few tons. Alongside these, Leadingpharm is also establishing solid trading and technical cooperative relationships with more than 20 pharmaceutical enterprises at home and abroad.